Quoted in Turna Ray’s GenomeWeb article about Athena v. Mayo, in which Athena Diagnostics has asked the Supreme Court to revisit its decision in Mayo v. Prometheus, 566 U.S. 66 (2012), holding that biological associations are unpatentable natural phenomena. Prometheus combined with AMP v. Myriad, 569 U.S. 576 (2013), to usher in the era of next generation sequencing. “‘The comments of some of the judges in this case were particularly disturbing to Roger Klein, who, as a trained pathologist and a legal consultant to labs and biotech firms, felt they displayed a misunderstanding of laboratory diagnostics and the discovery and translational process. ‘Mayo v Prometheus was a godsend for molecular genetic testing and an essential predicate to the progress we have made in applying massively parallel sequencing in clinical settings,’ said Klein, who was previously the medical director of molecular oncology at the Cleveland Clinic, and currently a faculty fellow in the Center for Law, Science, and Innovation at the Sandra Day O’Connor Law School at Arizona State University. ‘Without Mayo, there is no way we could routinely and inexpensively sequence many, hundreds or thousands of genes, exomes and genomes.'” https://www.360dx.com/policy-legislation/mayo-tells-supreme-court-congress-should-clarify-patent-eligibility-confusion#.XfFKhG5FwRB